Alterity Therapeutics Limited

ASX:ATH Stock Report

Market Cap: AU$16.0m

Alterity Therapeutics Management

Management criteria checks 3/4

Alterity Therapeutics' CEO is David Stamler, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is A$1.42M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth A$32.09K. The average tenure of the management team and the board of directors is 11.4 years and 18.5 years respectively.

Key information

David Stamler

Chief executive officer

AU$1.4m

Total compensation

CEO salary percentage50.4%
CEO tenure3.8yrs
CEO ownership0.2%
Management average tenure11.4yrs
Board average tenure18.5yrs

Recent management updates

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Nov 23
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Nov 23
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate

Jun 28
We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate

Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?

Mar 07
Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?

We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely

May 16
We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely

Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

Jan 31
Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?

Dec 09
How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?

CEO Compensation Analysis

How has David Stamler's remuneration changed compared to Alterity Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$717k

-AU$19m

Mar 31 2024n/an/a

-AU$16m

Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$13m

Jun 30 2023AU$2mAU$731k

-AU$14m

Mar 31 2023n/an/a

-AU$14m

Dec 31 2022n/an/a

-AU$14m

Sep 30 2022n/an/a

-AU$14m

Jun 30 2022AU$2mAU$658k

-AU$13m

Mar 31 2022n/an/a

-AU$13m

Dec 31 2021n/an/a

-AU$13m

Sep 30 2021n/an/a

-AU$14m

Jun 30 2021AU$979kAU$606k

-AU$15m

Mar 31 2021n/an/a

-AU$16m

Dec 31 2020n/an/a

-AU$16m

Sep 30 2020n/an/a

-AU$15m

Jun 30 2020AU$625kAU$625k

-AU$13m

Mar 31 2020n/an/a

-AU$13m

Dec 31 2019n/an/a

-AU$13m

Sep 30 2019n/an/a

-AU$12m

Jun 30 2019AU$548kAU$548k

-AU$12m

Mar 31 2019n/an/a

-AU$11m

Dec 31 2018n/an/a

-AU$10m

Sep 30 2018n/an/a

-AU$9m

Jun 30 2018AU$630kAU$504k

-AU$8m

Compensation vs Market: David's total compensation ($USD926.97K) is above average for companies of similar size in the Australian market ($USD298.50K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Stamler (63 yo)

3.8yrs

Tenure

AU$1,422,068

Compensation

Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...

Leadership Team

NamePositionTenureCompensationOwnership
Geoffrey Kempler
Co-Founder & Non-Executive Chairman27yrsAU$280.00k0.28%
A$ 44.4k
David Stamler
Chief Executive Officer3.8yrsAU$1.42m0.20%
A$ 32.1k
Abby Macnish Niven
Chief Financial Officerless than a yearno datano data
Rudolph Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board12.8yrsno datano data
Steven Targum
Chief Medical Advisor17.7yrsno datano data
Robert Cherny
Head of Research17.6yrsno datano data
Phillip Hains
Company Secretary10yrsno datano data

11.4yrs

Average Tenure

65.5yo

Average Age

Experienced Management: ATH's management team is seasoned and experienced (11.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Geoffrey Kempler
Co-Founder & Non-Executive Chairman27yrsAU$280.00k0.28%
A$ 44.4k
Rudolph Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board17.7yrsno datano data
Brian Meltzer
Non-Executive Independent Director24.9yrsAU$70.00k0.14%
A$ 22.4k
Colin Masters
Member of Research & Development Advisory Board17.7yrsAU$241.36kno data
Peter Marks
Non-Executive Independent Director19.3yrsAU$70.00k0.14%
A$ 21.6k
Lawrence Gozlan
Non-Executive Director13.3yrsAU$70.00kno data
Ira Shoulson
Chairman of Research & Development Advisory Boardno dataAU$78.76kno data

18.5yrs

Average Tenure

69yo

Average Age

Experienced Board: ATH's board of directors are seasoned and experienced ( 18.5 years average tenure).